Zacks Research Forecasts Stronger Earnings for Haemonetics

Haemonetics Corporation (NYSE:HAE) – Research analysts at Zacks Research increased their Q2 2028 earnings per share (EPS) estimates for Haemonetics in a report issued on Tuesday, March 24th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of $1.47 per share for the quarter, up from their prior forecast of $1.46. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share.

A number of other analysts have also recently weighed in on HAE. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Needham & Company LLC cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. JPMorgan Chase & Co. raised their price target on shares of Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Barrington Research set a $94.00 price target on Haemonetics in a report on Friday, February 6th. Finally, BTIG Research reiterated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and a consensus price target of $83.89.

Haemonetics Stock Performance

HAE stock opened at $53.96 on Friday. Haemonetics has a 1 year low of $47.31 and a 1 year high of $87.32. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of 14.86, a PEG ratio of 1.16 and a beta of 0.28. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75. The stock’s fifty day moving average is $62.27 and its two-hundred day moving average is $64.89.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business had revenue of $338.97 million for the quarter, compared to analysts’ expectations of $331.90 million. During the same period in the prior year, the firm earned $1.19 EPS. The business’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS.

Hedge Funds Weigh In On Haemonetics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. increased its stake in Haemonetics by 10,875.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 878 shares of the medical instruments supplier’s stock valued at $70,000 after buying an additional 870 shares during the period. World Investment Advisors bought a new stake in shares of Haemonetics during the 4th quarter worth about $246,000. Virtu Financial LLC acquired a new stake in shares of Haemonetics in the 4th quarter worth approximately $452,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Haemonetics in the 4th quarter worth approximately $509,000. Finally, EP Wealth Advisors LLC bought a new position in shares of Haemonetics in the fourth quarter valued at approximately $288,000. Institutional investors own 99.67% of the company’s stock.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.